Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

The Wilms' tumor gene 1 (WT1) induces expression of the N-myc downstream regulated gene 2 (NDRG2)

Author:
  • Emelie Svensson
  • Karina Vidovic
  • Tor Olofsson
  • Johan Vallon-Christersson
  • Åke Borg
  • Urban Gullberg
Publishing year: 2007
Language: English
Pages: 589-597
Publication/Series: DNA and Cell Biology
Volume: 26
Issue: 8
Document type: Journal article
Publisher: Mary Ann Liebert, Inc.

Abstract english

The Wilms' tumor gene 1 (WT1) protein is a transcriptional regulator that is highly expressed in immature hematopoietic progenitor cells and in the majority of patients with acute and chronic myeloid leukemia. However, it is still unclear how WT1 exerts its function(s) in hematopoietic cells. The aim of this work was to investigate the function of WT1 as a transcription factor in human hematopoietic progenitor cells. To this end, an oligonucleotide array approach was used to study the gene expression in CD34(+) cells from human cord blood retrovirally transduced with WT1 or a control vector. We found that the expression of the putative tumor suppressor gene N-myc downstream regulated gene 2 (NDRG2) mRNA was induced by WT1 in CD34(+) cells and also in leukemic U937 cells. Furthermore, a novel transcription start site in the NDRG2 gene was identified in WT1-transduced cells, in addition to two previously reported transcription start sites. These results show that the expression of the NDRG2 gene is directly or indirectly induced by WT1, and provide the first insights into transcriptional regulation of the NDRG2 gene, including demonstration of a novel splice variant.

Keywords

  • Hematology
  • Cancer and Oncology

Other

Published
  • CREATE Health
  • ISSN: 1044-5498
Åke Borg
Åke Borg
E-mail: ake [dot] borg [at] med [dot] lu [dot] se

Principal investigator

Oncology and Pathology, MV

+46 46 275 25 52

MV 404 C21B2

90

Project manager

Familial Breast Cancer

90

Professor

Oncology and Pathology, MV

MV 404 C21C2

90